The study reported that changes in gut microbial composition occurred following treatment initiation, and that baseline gut microbiome profiles were associated with subsequent improvements in glycaemic control. Gut Microbiome and Diabetes Treatment ResponseThe gut microbiome, which refers to the community of microorganisms residing in the gastrointestinal tract, has increasingly been recognised as a key modulator of metabolic health. The researchers found that both semaglutide and empagliflozin use were associated with shifts in gut microbial community structure after treatment initiation. Clinical Implications and Future DirectionsThese findings positioned the gut microbiome as a potential biomarker for personalised diabetes treatment, aligning with broader efforts to tailor therapy based on biological signatures rather than trial-and-error prescribing. Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake.